Broad Based Antiviral

Equivir

Equivir

Patented nutraceutical formula of combined polyphenols for Over the Counter (OTC) medication. This successfully tested in vitro against Rhinovirus, Influenza, Cholera, SARS-CoV-2 (COVID-19) and in a Biosafety Level 4 facility, Ebola. Equivir is both a treatment and a prophylactic for COVID-19 and is moving to human clinical trials.

 

EQUIVIR G

Patented nutraceutical formula of combined polyphenols. This technology is being positioned to go the traditional drug route to allow full antiviral claims. The formula has been specifically designed for inhibition of RdRp of the SARS-COV2 virus.

Research

  • ProPhase Labs

    ProPhase BioPharma, a wholly owned subsidiary of Prophase Labs, is working with Vedic Lifesciences on clinical trials of Equivir (OTC) to evaluate its effect on upper respiratory tract infections for both prophylactic and therapeutic uses.

Project Details

Equivir is a broad based antiviral that is being studied for prophylactic and therapeutic use as an OTC dietary supplement. Equivir G is a patented nutraceutical formula being researched as a full antiviral drug.

Patents
  • 1
    10,383,842
  • 2
    11,311,563
Partnerships

  • Equivir and Equivir G have been licensed to ProPhase Labs through Impact Biomedical with a focus on releasing an OTC Equivir for sale in Q4 of 2023, and following the traditional drug route to allow full antiviral claims for Equivir G.